Regulation of the apolipoprotein M signaling pathway: a review

References

• Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem. 1999;274(44):31286–31290.
   PubMed Web of Science ®Google Scholar
• Christoffersen C, Ahnstrom J, Axler O, et al. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem. 2008;283(27):18765–18772.
   PubMed Web of Science ®Google Scholar
• Axler O, Ahnstrom J, Dahlback B. Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett. 2008;582(5):826–828.
   PubMed Web of Science ®Google Scholar
• Faber K, Hvidberg V, Moestrup SK, et al. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol. 2006;20(1):212–218.
   PubMedGoogle Scholar
• Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011;108(23):9613–9618.
   PubMed Web of Science ®Google Scholar
• Sevvana M, Ahnstrom J, Egerer-Sieber C, et al. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol. 2009;393(4):920–936.
   PubMed Web of Science ®Google Scholar
• Ruiz M, Okada H, Dahlbäck B. HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium. Lipids Health Dis. 2017;16(1):36.
   PubMedGoogle Scholar
• Zheng Z, Zeng Y, Zhu X, et al. ApoM-S1P modulates Ox-LDL-induced inflammation through the PI3K/Akt signaling pathway in HUVECs. Inflammation. 2019;42(2):606–617.
   PubMed Web of Science ®Google Scholar
• Liu D, Pan JM, Pei X, et al. Interaction between apolipoprotein M gene single-nucleotide polymorphisms and obesity and its effect on type 2. Sci Rep. 2020;10(1):7859.
   PubMed Web of Science ®Google Scholar
• Zhang PH, Gao JL, Pu C, et al. A single-nucleotide polymorphism C-724/del in the proter region of the apolipoprotein M gene is associated with type 2 diabetes mellitus. Lipids Health Dis. 2016;15(1):142.
   PubMedGoogle Scholar
• Liu M, Frej C, Langefeld CD, et al. Plasma apoM and S1P levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus. J Lipid Res. 2019;60(8):1425–1431.
   PubMed Web of Science ®Google Scholar
• Hajny S, Christoffersen M, Dalila N, et al. Apolipoprotein M and risk of type 2 diabetes. J Clin Endocrinol Metab. 2020;105(9):dgaa433.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang J, Qiao Y, et al. Apolipoprotein M gene single nucleotide polymorphisms discovery in patients with chronic obstructive pulmonary disease and determined by the base-quenched probe technique. Gene. 2017;637:9–13.
   PubMed Web of Science ®Google Scholar
• Du W, Shen T, Li H, et al. Low apolipoprotein M serum levels correlate with Systemic lupus erythematosus disease activity and apolipoprotein M gene polymorphisms with Lupus. Lipids Health Dis. 2017;16(1):88.
   PubMedGoogle Scholar
• Kurano M, Hara M, Tsuneyama K, et al. Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate. Biochim Biophys Acta. 2014;1841(9):1217–1226.
   PubMed Web of Science ®Google Scholar
• Yao S, Zhang J, Zhan Y, et al. Insulin resistance in apolipoprotein M knockout mice is mediated by the protein kinase Akt signaling pathway. Endocr Metab Immune Disord Drug Targets. 2020;20(5):771–780.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang J, Yao S, et al. Apolipoprotein M overexpression through adeno-associated virus gene transfer improves insulin secretion and insulin sensitivity in Goto-Kakizaki rats. J Diabetes Investig. 2020;11(5):1150–1158.
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11(4):418–422.
   PubMed Web of Science ®Google Scholar
• Mulya A, Seo J, Brown AL, et al. Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J Lipid Res. 2010;51(3):514–524.
   PubMed Web of Science ®Google Scholar
• Faber K, Axler O, Dahlback B, et al. Characterization of apoM in normal and genetically modified mice. J Lipid Res. 2004;45(7):1272–1278.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Dong X, Zheng L, et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem. 2003;105(1):67–72.
   PubMed Web of Science ®Google Scholar
• Sramkova V, Berend S, Siklova M, et al. Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction. Am J Clin Nutr. 2019;109(6):1499–1510.
   PubMed Web of Science ®Google Scholar
• Kober AC, Manavalan APC, Tam-Amersdorfer C, et al. Implications of cerebrovascular ATP-binding cassette transporter G1 (ABCG1) and apolipoprotein M in cholesterol transport at the blood-brain barrier. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(6):573–588.
   PubMed Web of Science ®Google Scholar
• Ma X, Hu YW, Zhao ZL, et al. Anti-inflammatory effects of propofol are mediated by apolipoprotein M in a hepatocyte nuclear factor-1alpha-dependent manner. Arch Biochem Biophys. 2013;533(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhao S. Effect of simvastatin on the expression and regulation mechanism of apolipoprotein M. Int J Mol Med. 2012;29(3):510–514.
   PubMed Web of Science ®Google Scholar
• Cai H, Yao W, Huang J, et al. Apolipoprotein M, identified as a novel hepatitis C virus (HCV) particle associated protein, contributes to HCV assembly and interacts with E2 protein. Antiviral Res. 2020;177:104756.
   PubMed Web of Science ®Google Scholar
• Ding BS, Yang D, Swendeman SL, et al. Aging suppresses sphingosine-1-phosphate chaperone ApoM in circulation resulting in maladaptive organ repair. Dev Cell. 2020;53(6):677–690 e4.
   PubMed Web of Science ®Google Scholar
• Calayir E, Becker TM, Kratzer A, et al. LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr Pharm Biotechnol. 2008;9(6):516–521.
   PubMed Web of Science ®Google Scholar
• Zhu C, Di D, Zhang X, et al. TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells. Lipids Health Dis. 2011;10(1):199.
   PubMedGoogle Scholar
• Wolfrum C, Howell JJ, Ndungo E, et al. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem. 2008;283(24):16940–16949.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhao J, Zhao Z, et al. Propofol attenuates lipopolysaccharide-induced monocyte chemoattractant protein-1 production through enhancing apoM and foxa2 expression in HepG2 cells. Inflammation. 2015;38(3):1329–1336.
   PubMed Web of Science ®Google Scholar
• Venteclef N, Haroniti A, Tousaint JJ, et al. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J Biol Chem. 2008;283(7):3694–3701.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhou HG, Zhou H, et al. Apolipoprotein M regulates the orphan nuclear receptor LRH-1 gene expression through binding to its promoter region in HepG2 cells. Drug Des Devel Ther. 2015;9:2375–2382.
   PubMed Web of Science ®Google Scholar
• Luo G, Feng Y, Zhang J, et al. Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver. Int J Med Sci. 2014;11(10):1015–1021.
   PubMed Web of Science ®Google Scholar
• Kurano M, Ikeda H, Iso ON, et al. Regulation of the metabolism of apolipoprotein M and sphingosine 1-phosphate by hepatic PPARgamma activity. Biochem J. 2018;475(12):2009–2024.
   PubMedGoogle Scholar
• Xue HX, Li HF, Wang T, et al. LncRNA HCG11 suppresses laryngeal carcinoma cells progression via sponging miR-4469/APOM axis. Eur Rev Med Pharmacol Sci. 2020;24(6):3174–3182.
   PubMed Web of Science ®Google Scholar
• Di D, Wang Z, Liu Y, et al. ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells. Biochem Biophys Res Commun. 2012;421(1):152–156.
   PubMed Web of Science ®Google Scholar
• Wei J, Yu Y, Luo GH, et al. 17beta-estradiol regulates the expression of apolipoprotein M through estrogen receptor alpha-specific binding motif in its promoter. Lipids Health Dis. 2017;16(1):66.
   PubMedGoogle Scholar
• Luo G, Shi Y, Zhang J, et al. Palmitic acid suppresses apolipoprotein M gene expression via the pathway of PPARbeta/delta in HepG2 cells. Biochem Biophys Res Commun. 2014;445(1):203–207.
   PubMed Web of Science ®Google Scholar
• Yang L, Li T. LncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR-92a/FXR1 axis. J Cell Mol Med. 2020;24(15):8836–8848.
   PubMed Web of Science ®Google Scholar
• Ren K, Mo ZC, Liu X, et al. TGF-beta down-regulates apolipoprotein M expression through the TAK-1-JNK-c-Jun pathway in HepG2 cells. Lipids. 2017;52(2):109–117.
   PubMed Web of Science ®Google Scholar
• Richter S, Shih DQ, Pearson ER, et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes. 2003;52(12):2989–2995.
   PubMed Web of Science ®Google Scholar
• Mosialou I, Krasagakis K, Kardassis D. Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem. 2011;286(19):17259–17269.
   PubMed Web of Science ®Google Scholar
• Cervin C, Axler O, Holmkvist J, et al. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med. 2010;267(3):316–321.
   PubMed Web of Science ®Google Scholar
• Mosialou I, Zannis VI, Kardassis D. Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem. 2010;285(40):30719–30730.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Z, Luo G, et al. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun. 2008;371(1):114–117.
   PubMed Web of Science ®Google Scholar
• Zhao J, Hu Y, Li S, et al. Dihydrocapsaicin down-regulates apoM expression through inhibiting Foxa2 expression and enhancing LXRα expression in HepG2 cells. Lipids Health Dis. 2014;13(1):50.
   PubMedGoogle Scholar
• Yang L, Li T, Zhao S, et al. Niacin regulates apolipoprotein M expression via liver X receptor-α. Mol Med Rep. 2019 Oct;20(4):3285–3291.
   PubMed Web of Science ®Google Scholar
• Fayard E, Auwerx J, Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol. 2004;14(5):250–260.
   PubMed Web of Science ®Google Scholar
• Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6(3):507–515.
   PubMed Web of Science ®Google Scholar
• del Castillo-Olivares A, Campos JA, Pandak WM, et al. The role of alpha1-fetoprotein transcription factor/LRH-1 in bile acid biosynthesis: a known nuclear receptor activator that can act as a suppressor of bile acid biosynthesis. J Biol Chem. 2004;279(16):16813–16821.
   PubMed Web of Science ®Google Scholar
• Schwaderer J, Phan TS, Glockner A, et al. Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis. Cell Death Dis. 2020;11(2):154.
   PubMed Web of Science ®Google Scholar
• Bianco S, Jangal M, Garneau D, et al. LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression. Oncogene. 2015;34(34):4509–4518.
   PubMed Web of Science ®Google Scholar
• Seitz C, Huang J, Geiselhoringer AL, et al. The orphan nuclear receptor LRH-1/NR5a2 critically regulates T cell functions. Sci Adv. 2019;5(7):eaav9732.
   PubMed Web of Science ®Google Scholar
• Boulias K, Katrakili N, Bamberg K, et al. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. Embo J. 2005;24(14):2624–2633.
   PubMed Web of Science ®Google Scholar
• Andraski AB, Singh SA, Lee LH, et al. Effects of replacing dietary monounsaturated fat with carbohydrate on HDL (high-density lipoprotein) protein metabolism and proteome composition in humans. Arterioscler Thromb Vasc Biol. 2019;39(11):2411–2430.
   PubMed Web of Science ®Google Scholar
• Christoffersen C, Pedersen TX, Gordts PL, et al. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. Circ Res. 2010;106(10):1624–1634.
   PubMed Web of Science ®Google Scholar
• Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316(5822):295–298.
   PubMed Web of Science ®Google Scholar
• Galvani S, Sanson M, Blaho VA, et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015;8(389):ra79.
   PubMed Web of Science ®Google Scholar
• Burg N, Swendeman S, Worgall S, et al. Sphingosine 1-phosphate receptor 1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury. Arthritis Rheumatol. 2018;70(11):1879–1889.
   PubMed Web of Science ®Google Scholar
• Argraves KM, Gazzolo PJ, Groh EM, et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem. 2008;283(36):25074–25081.
   PubMed Web of Science ®Google Scholar
• Terao R, Honjo M, Totsuka K, et al. The role of sphingosine 1-phosphate receptors on retinal pigment epithelial cells barrier function and angiogenic effects. Prostaglandins Other Lipid Mediat. 2019;145:106365.
   PubMed Web of Science ®Google Scholar
• Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 2007;21(4):1202–1209.
   PubMed Web of Science ®Google Scholar
• Christensen PM, Bosteen MH, Hajny S, et al. Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes. Sci Rep. 2017;7(1):14983.
   PubMedGoogle Scholar
• Aoki S, Yatomi Y, Ohta M, et al. Sphingosine 1-phosphate-related metabolism in the blood vessel. J Biochem. 2005;138(1):47–55.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kurano M, Nanya M, et al. Glycation of HDL polymerizes apolipoprotein M and attenuates its capacity to bind to sphingosine 1-phosphate. J Atheroscler Thromb. 2020;27.
   Google Scholar
• Blaho VA, Galvani S, Engelbrecht E, et al. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature. 2015;523(7560):342–346.
   PubMed Web of Science ®Google Scholar
• Christensen PM, Liu CH, Swendeman SL, et al. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1. FASEB J. 2016;30(6):2351–2359.
   PubMed Web of Science ®Google Scholar
• Mathiesen Janiurek M, Soylu-Kucharz R, Christoffersen C, et al. Apolipoprotein M-bound sphingosine-1-phosphate regulates blood-brain barrier paracellular permeability and transcytosis. Elife. 2019;8:e49405.
   PubMed Web of Science ®Google Scholar
• Swendeman SL, Xiong Y, Cantalupo A, et al. An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci Signal. 2017;10(492):eaal2722.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhang H. Molecular mechanism of S1P binding and activation of the S1P1 receptor. J Chem Inf Model. 2019;59(10):4402–4412.
   PubMed Web of Science ®Google Scholar
• Morales-Ruiz M, Lee MJ, Zollner S, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276(22):19672–19677.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tie L. Apolipoprotein M and sphingosine-1-phosphate complex alleviates TNF-alpha-induced endothelial cell injury and inflammation through PI3K/AKT signaling pathway. BMC Cardiovasc Disord. 2019;19(1):279.
   PubMed Web of Science ®Google Scholar
• Gao JJ, Hu YW, Wang YC, et al. ApoM suppresses TNF-alpha-induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-kappaB. DNA Cell Biol. 2015;34(8):550–556.
   PubMed Web of Science ®Google Scholar
• Del Gaudio I, Hendrix S, Christoffersen C, et al. Neonatal HDL counteracts placental vascular inflammation via S1P-S1PR1 axis. Int J Mol Sci. 2020;21(3):789.
   Web of Science ®Google Scholar
• Frej C, Mendez AJ, Ruiz M, et al. A shift in ApoM/S1P between HDL-particles in women with type 1 diabetes mellitus is associated with impaired anti-inflammatory effects of the ApoM/S1P complex. Arterioscler Thromb Vasc Biol. 2017;37(6):1194–1205.
   PubMed Web of Science ®Google Scholar
• Kurano M, Tsukamoto K, Shimizu T, et al. Protection against insulin resistance by apolipoprotein M/sphingosine-1-phosphate. Diabetes. 2020;69(5):867–881.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Luo G, Jiang B, et al. Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways. Biochem Biophys Res Commun. 2018;501(2):520–526.
   PubMed Web of Science ®Google Scholar
• Yu M, Pan L, Sang C, et al. Apolipoprotein M could inhibit growth and metastasis of SMMC7721 cells via vitamin D receptor signaling. Cancer Manag Res. 2019;11:3691–3701.
   PubMed Web of Science ®Google Scholar
• Kurano M, Tsuneyama K, Morimoto Y, et al. Apolipoprotein M protects lipopolysaccharide-treated mice from death and organ injury. Thromb Haemost. 2018;118(6):1021–1035.
   PubMed Web of Science ®Google Scholar